TCT 649: Impact of a Novel Hybrid Nano-coated Nitinol Drug-eluting Stent (Hybrid-DES) on Below-the-knee Atherosclerotic Disease: 2023 Update

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Consultant Fee/Honoraria/Speaker’s Bureau - Stryker Corporation